Previous 10 | Next 10 |
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, e...
The following slide deck was published by Molecular Templates, Inc. in conjunction with this event. For further details see: Molecular Templates (MTEM) Investor Presentation - slideshow
AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin b...
The recent market pullback was arguably overdue and is already making stocks attractive for longer-term investors. Insiders are giving excellent industry signals to act on and numerous specific stocks to consider. Take your pick of insider-approved energy, bank, income, infrastruc...
Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in 2H22 MTEM to Present at Evercore ISI 4 th Annual HealthCON...
Molecular Templates (NASDAQ:MTEM) announces that the FDA has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer expressing PD-L1. Shares up 8% premarket at $5.10. Fast Track status provides for more frequent interaction ...
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...
Molecular Templates (NASDAQ:MTEM): Q3 GAAP EPS of -$0.54 misses by $0.19. Revenue of $2.38M (-44.7% Y/Y) misses by $9.75M. Press Release For further details see: Molecular Templates EPS misses by $0.19, misses on revenue
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...
The following slide deck was published by Molecular Templates, Inc. in conjunction with this event. For further details see: Molecular Templates (MTEM) presents at 2021 Oppenheimer Healthcare Conference
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...